Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study

医学 阿帕蒂尼 脊索瘤 相(物质) 外科 总体生存率 物理 量子力学
作者
Chao Liu,Qi Jia,Haifeng Wei,Xinghai Yang,Tielong Liu,Jian Zhao,Ling Yan,Chenguang Wang,Hongyu Yu,Zhenxi Li,Jian Jiao,Zhipeng Wu,Cheng Zhi Yang,Jianru Xiao
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (9): 1244-1252 被引量:70
标识
DOI:10.1016/s1470-2045(20)30466-6
摘要

Summary

Background

No standard treatment exists for advanced chordoma. Apatinib has been found to have promising efficacy and manageable adverse effects for the treatment of solid tumours. We aimed to investigate the safety and antitumour activity of apatinib in patients with advanced chordoma.

Methods

We did a single-arm, phase 2 study at one tertiary hospital in Shanghai, China. Eligible patients were aged 18–75 years, with histologically confirmed advanced chordoma that was unresectable or resectable only through demolitive surgery, who had previously received surgical treatment, with at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, evidence of tumour progression on enhanced CT or MRI in the previous 6 months, and an Eastern Cooperative Oncology Group performance status of 0–2. Patients received oral 500 mg apatinib once daily until disease progression or unacceptable toxicity. The co-primary endpoints were progression-free survival and objective response rate according to RECIST 1.1 and Choi criteria by investigator assessment. Progression-free survival was assessed in the intention-to-treat population. Objective response rate was assessed in the per-protocol population, which included all enrolled patients who were compliant with the protocol and had at least one post-baseline assessment. Safety was analysed in all patients with complete safety data. This study is ongoing, but recruitment is complete. This study is registered with Chictr.org.cn, ChiCTR-OIC-17013586.

Findings

Between Aug 21, 2017, and May 31, 2019, we screened 32 patients, of whom 30 were enrolled. Median follow-up was 14·2 months (IQR 9·4–19·7). Of the 27 patients included in the per-protocol population, one patient (3·7%; 95% CI 0–11·3) achieved an objective response according to RECIST, and seven patients (25·9%; 8·3–43·6) achieved an objective response according to Choi criteria. Median progression-free survival was 18 months (95% CI 3–34) according to RECIST and 18 months (3–33) according to Choi criteria. The most common treatment-related grade 3 adverse events were hypertension (seven [24%] of 29 patients) and proteinuria (two [7%]). No treatment-related grade 4 adverse events or treatment-related deaths were observed.

Interpretation

To our knowledge, this is the first trial of apatinib for the treatment of advanced chordoma. Apatinib shows promising activity and manageable toxicity and thus might be an option for the treatment of advanced chordoma.

Funding

None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
许右发布了新的文献求助10
1秒前
haha发布了新的文献求助10
1秒前
科研通AI6.3的应助被杨淼采纳,获得10
2秒前
2秒前
激动的元瑶完成签到 ,获得积分10
3秒前
3秒前
研雾完成签到,获得积分10
4秒前
maoqiuzhao发布了新的文献求助10
5秒前
molihuakai的应助被文献互助1采纳,获得10
5秒前
bkagyin的应助被rose采纳,获得10
5秒前
maoamo2024发布了新的文献求助10
6秒前
yu完成签到,获得积分10
6秒前
田様的应助被路小雨采纳,获得10
6秒前
6秒前
6秒前
久睡成瘾完成签到,获得积分10
7秒前
清辉影的应助被yuxing采纳,获得10
7秒前
Jan完成签到,获得积分0
7秒前
Tuniverse_发布了新的文献求助10
8秒前
温柔的百川完成签到,获得积分10
8秒前
喂喂喂发布了新的文献求助10
9秒前
Yaoz完成签到,获得积分10
9秒前
许元冬完成签到,获得积分10
9秒前
zft完成签到,获得积分10
9秒前
KBRS完成签到,获得积分10
10秒前
MM完成签到,获得积分10
11秒前
雪雪完成签到,获得积分10
12秒前
Yaoz发布了新的文献求助30
13秒前
明亮绮菱发布了新的文献求助10
13秒前
xiang完成签到,获得积分10
15秒前
15秒前
缥缈幻悲完成签到,获得积分10
15秒前
王明月完成签到,获得积分10
16秒前
彭映梦完成签到 ,获得积分10
17秒前
小小酥被卷了完成签到,获得积分10
18秒前
科研通AI6.4的应助被obito采纳,获得10
20秒前
天真酸奶的应助被obito采纳,获得10
20秒前
CipherSage的应助被明亮绮菱采纳,获得10
20秒前
王明月发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621